title: Clinical breast cancer, new developments in selection and endocrine treatment of patients.
abstract: Breast cancer is the most common malignant tumor among women, comprising an estimated 24% of all cancer cases and 18% of all cancer deaths. At least half of the patients with primary breast cancer will ultimately die by metastatic disease. The tumor characteristics, the natural course of the disease and the response to therapy vary strongly. A number of recently detected cell biological parameters such as oncogenes/suppressor genes, growth factors and secretory proteins are more or less important prognostic factors, because they influence the characteristics and behavior of a tumor with respect to metastatic pattern, extent of cellular differentiation, growth rate and response to treatment. However, there is no clear consensus how best to identify patients at high or low risk. In our experience c-myc amplification and pS2 protein are strong prognosticators for relapse rate, while in advanced disease (apart from a negative estrogen/progesterone receptor/pS2 status) amplification of HER2/neu is a good prognosticator for failure to endocrine therapy. In the diagnosis of breast cancer, in vivo imaging of tumors by labeled hormones or other factors also forms a new development which might have implications for treatment too. With respect to treatment both endocrine and chemotherapy can cure a minority of patients with micrometastases, but in patients with advanced disease only a prolongation of (progression-free) survival can be reached. Response rates decrease with increasing tumor load. In the past decade a number of interesting new endocrine agents has been developed such as new (pure) (anti)steroidal agents, vitamins, aromatase inhibitors, analogs of peptide hormones, prolactin inhibitors and growth factor antagonists. However, less is known on the (potential) interaction between hormones, chemotherapeutic agents, retinoids, cytokins, growth factor antagonists and irradiation. Rapid detection of new powerful combination therapies are needed to improve treatment results during the nineties.
authors.affiliation: Division of Endocrine Oncology, Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
authors.forename: J G
authors.initials: JG
authors.lastname: Klijn
authors.forename: P M
authors.initials: PM
authors.lastname: Berns
authors.forename: M
authors.initials: M
authors.lastname: Bontenbal
authors.forename: J
authors.initials: J
authors.lastname: Alexieva-Figusch
authors.forename: J A
authors.initials: JA
authors.lastname: Foekens
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D011379:Prognosis
chemical_list: D006728:Hormones